Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 21

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 21
---
 one Series E
Warrant, and (c) one Series F Warrant. The aggregate gross proceeds to the Company were approximately $6.0 million. Additionally, we
issued warrants to purchase 480 of our Depositary Shares in connection with the offering to the underwriter, or the December 2023 Underwriter
Warrants.

On February 26, 2024,
in connection with our Company’s obligations under a license agreement with Melior, we issued 1,417 Depositary Shares to Bukwang
Pharmaceutical Co. Ltd., or Bukwang.

On April 29, 2024, in
connection with the closing of a license agreement, we issued 1,512 Depositary Shares to Emtora.

On May 24, 2024, in connection
with the transactions contemplated by certain warrant inducement letters, or the Warrant Agreement, we issued an aggregate of 12,417
Depositary Shares to certain holders of our Series E Warrants and Series F Warrants, upon the exercise of 6,290 Series E Warrants and
6,127 Series F Warrants, at an exercise price of $375.00 per share. In addition, we issued to such holders an aggregate of 9,434 Series
G warrants, or the Series G Warrants, and 14,780 Series H Warrants. The aggregate gross proceeds to the Company were approximately $6.05
million, before deducting agent fees and expenses. Additionally, we issued warrants to purchase 644 of our Depositary Shares in connection
with the offering to the warrant agent and certain of their designees, or Warrant Agent Warrants.

Between December 21,
2023 and June 30, 2025, we have issued 2,952,928,400 Ordinary Shares upon the exercise of the pre-funded warrants, Series E Warrants
and Series F Warrants issued in the December 2023 underwritten public offering and December 2023 Private Placement, including warrants
exercised pursuant to the terms of the Warrant Agreements (other than shares held in abeyance).

| 15 |

On July 22, 2024, we
sold in a registered direct offering an aggregate of (i) 20,203 Depositary Shares and (ii) 1,114 pre-funded warrants, or July 2024 Pre-Funded
Warrants, at a price per Depositary Share of $235.00, and a price per July